Development and characterisation of Affimer binders to 4 leading therapeutic antibodies

Antibodies represent established affinity reagents for use in the regulatory bioanalysis of biologics. Yet, these reagents are associated with limitations that often present challenges with supply, stability and batch-to-batch variation on assay performance.

Our new application note outlines our established development and characterisation process for Affimer binders to four of the leading therapeutic antibodies- Trastuzumab, Rituximab, Adalimumab and Ipilimumab- for use as PK assay reagents.

Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.

Click to view all articles for the EPIC: AVCT
Or click to view the full company profile:
Avacta Group Plc

Avacta Group deliver major value inflection points during the first weeks of 2021

24th February 2021

Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, has provided a business update for the 12 months ended 31 December 2020 and post-period. Preliminary results for the financial year ended

Avacta Group receives MHRA approval for Phase I Clinical Trial Authorisation for AVA6000

18th February 2021

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for its Clinical Trial Authorisation (CTA) in the UK for a phase I

Avacta Group Excellent data for the first clinical evaluation of lateral flow antigen test (Interview)

17th February 2021

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss first clinical evaluation of lateral flow antigen test. Alastair talks us through the data and explains the next steps in taking the test to market.

Avacta Group geared up to bring high quality, high volume lateral flow antigen test to market (Interview)

8th February 2021

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss its partnership with Mologic. Alastair talks us through the details of the agreement, expands on the additional manufacturing capacity, explains how it will develop develop other

Avacta plc notice regarding publication error

20th January 2021

Regarding a recent aggregated news article published earlier today, which has since been taken down, this was an error on the DirectorsTalk part linking to old news. This was nothing to do with Avacta Plc. The

Avacta inks radiopharma deal with POINT Biopharma

12th January 2021

UK-based Avacta Group (AIM: AVCT) has entered into a license agreement with Canadian firm POINT Biopharma to provide access to Avacta’s pre|CISION technology for the development of tumor-activated radiopharmaceuticals. The radiopharmaceutical market is expected to grow

Avacta signs new cancer therapy deal

8th January 2021

Avacta Group, the developer of innovative cancer therapies, has entered into a license agreement with Point Biopharma to provide access to Avacta’s technology for the development of tumour-activated radiopharmaceuticals. Radiopharmaceutical therapy is now seen as a

Avacta Group license agreement with POINT Biopharma to utilise pre|CISION FAP sensitive activation platform

7th January 2021

Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced that it has entered into a license agreement with POINT Biopharma Inc., to provide access to Avacta’s

Research looks to improve wastewater testing for COVID-19

5th January 2021

Accurately identifying changes in community COVID-19 infections through wastewater surveillance is moving closer to reality. A new study, published in Environmental Science & Technology, identifies a method that not only detects the virus in wastewater samples but also

Hopes for clinical trial on humans of tumour targeting drug

29th December 2020

Hopes for clinical trial of tumour targeting drug by Avacta. The company has filed an application for phase one testing, for its pre|CISION prodrug AVA6000. If approved, it will be tested on patients with metastatic solid tumours. The

Avacta Group submits Clinical Trial Application for AVA6000 Pro-doxorubixin

23rd December 2020

Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, has announced that it has submitted a Clinical Trial Application (CTA) in the UK for a Phase 1, first-in-human,

Gamma Biosciences announces strategic licensing agreement by Astrea Bioseparations with Avacta

22nd December 2020

Gamma Biosciences, a life sciences tools platform created by KKR, has announced a licensing agreement between Astrea Bioseparations, a leader in affinity chromatography and bioseparations, and Avacta, a developer of innovative cancer therapies and diagnostics based

Avacta Group agreement with Astrea Bioseparations ‘the perfect deal’

22nd December 2020

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the agreement with Astrea Bioseparations. Alastair explains what affinity separation is, tell us about the market, the details of the deal, how it fits in with

Avacta Group license agreement with Astrea Bioseparations for affinity purification applications

21st December 2020

Avacta finalists in the 2020 Cambridge Independent Science and Technology Awards

15th December 2020

The finalists in the 2020 Cambridge Independent Science and Technology Awards can now be revealed. Following hundreds of entries, a shortlist across 14 categories has been drawn up. Biotech Company of the Year Covid-19 Response Award, sponsored by

Avacta’s progress of the lateral flow SARS-CoV-2 antigen test

8th December 2020

Avacta Group has announced progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good

BioSpace global roundup

3rd December 2020

U.K.-based Avacta Group announced significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical

Talks could trigger COVID test rollout

27th November 2020

Cambridge biotech Avacta Group is in discussions with commercial partners to establish a route to market for a CE marked BAMS COVID-19 test that can be deployed in hospitals in the UK and Europe. It is

Be sure to check our sister interview main ratings news website